Artivion (NYSE:AORT) SVP Sells $59,530.92 in Stock

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 1,668 shares of the firm’s stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $35.69, for a total value of $59,530.92. Following the completion of the transaction, the senior vice president directly owned 152,203 shares of the company’s stock, valued at $5,432,125.07. The trade was a 1.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Artivion Stock Performance

Shares of NYSE:AORT traded up $0.31 during midday trading on Wednesday, reaching $35.66. 300,261 shares of the company traded hands, compared to its average volume of 399,410. The firm’s fifty day moving average price is $42.51 and its two-hundred day moving average price is $43.14. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of 178.32 and a beta of 1.59. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $48.25.

Artivion (NYSE:AORT) last issued its earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The business had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. The company’s quarterly revenue was up 19.2% on a year-over-year basis. On average, equities analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Oppenheimer reaffirmed an “outperform” rating and issued a $50.00 price target on shares of Artivion in a report on Friday, November 7th. Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Citizens Jmp boosted their target price on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Finally, Canaccord Genuity Group lowered their price target on Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $48.97.

Hedge Funds Weigh In On Artivion

Institutional investors have recently modified their holdings of the company. Summit Partners Public Asset Management LLC bought a new stake in Artivion in the 4th quarter worth approximately $39,401,000. Invesco Ltd. grew its position in Artivion by 211.9% during the fourth quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock valued at $50,228,000 after acquiring an additional 748,119 shares during the last quarter. Champlain Investment Partners LLC purchased a new position in shares of Artivion during the third quarter worth approximately $17,912,000. Goldman Sachs Group Inc. raised its stake in shares of Artivion by 144.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 537,375 shares of the company’s stock worth $24,510,000 after acquiring an additional 317,518 shares in the last quarter. Finally, Two Sigma Investments LP grew its holdings in shares of Artivion by 235.5% during the 3rd quarter. Two Sigma Investments LP now owns 446,535 shares of the company’s stock valued at $18,906,000 after purchasing an additional 313,446 shares during the last quarter. 86.37% of the stock is currently owned by institutional investors.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.